Por favor, use este identificador para citar o enlazar este ítem: http://sgc.anlis.gob.ar/handle/123456789/2634
Título : National Multicenter Study on the Prevalence of Carbapenemase-Producing Enterobacteriaceae in the Post-COVID-19 Era in Argentina: The RECAPT-AR Study
Autor : Echegorry, Mariano 
Marchetti, Paulina 
Sanchez, Cristian 
Olivieri, Laura 
Faccone, Diego 
Martino, Florencia 
Sarkis Badola, Tomas 
Ceriana, Paola G. 
Rapoport, Melina J. 
Lucero, María Celeste 
Albornoz, Ezequiel 
Recapt-AR Group 
Corso, Alejandra 
Pasteran, Fernando 
Palabras clave : Enterobacteriaceae Resistentes a los Carbapenémicos;Resistencia antimicrobiana;COVID-19;Argentina
Fecha de publicación : 27-nov-2024
Citación : Antibiotics (Basel);2024 Nov 27;13(12):1139
Resumen : 
The COVID-19 pandemic has exacerbated the global antimicrobial resistance (AMR)
crisis. Consequently, it is more urgent than ever to prioritize AMR containment
and support countries in improving the detection, characterization, and rapid
response to emerging AMR threats. We conducted a prospective, multicenter study
to assess the prevalence of carbapenemase-producing Enterobacterales in
infectious processes in Argentina during the post-COVID-19 pandemic period and
explore therapeutic alternatives for their treatment (RECAPT-AR study). METHODS:
A total of 182 hospitals participated by submitting Enterobacterales clinical
isolates to the National Reference Laboratory (NRL) during the first three weeks
of November 2021. Inclusion criteria were defined as an ertapenem MIC ≥ 0.5 mg/L,
a zone diameter ≤ 22 mm. Carbapenemase genes and those coding for major
extended-spectrum β-lactamases were molecularly characterized using multiplex PCR
at the NRL. Antibiotic susceptibility testing followed international standards
(CLSI and EUCAST). RESULTS: The NRL analyzed 821 Enterobacterales isolates.
Metallo-β-lactamase (MBL, 42.0%) and KPC (39.8%) accounted for 81.8% of
carbapenemases, followed by OXA-163 (7.4%), a variant of OXA-48 with additional
activity against extended-spectrum cephalosporins, and enzyme combinations
(8.3%). These combinations included NDM plus KPC (3.4%), OXA-163 plus KPC (2.4%),
and OXA-163 plus NDM (2.1%). Klebsiella pneumoniae was the main species
recovered, representing 76% of the isolates. According to the carbapenemase
classes or combinations, tigecycline exhibited a susceptibility range of 33-83%,
fosfomycin 59-81%, colistin 27-78%, and amikacin 17-81%. Ceftazidime-avibactam
(CZA) and imipenem-relebactam (IMR) showed 92% and 98% susceptibility against
serine carbapenemases, respectively. Meanwhile, aztreonam-avibactam (AZA)
exhibited 96-98% susceptibility against all carbapenemase classes. CONCLUSIONS: A
new epidemiological landscape has emerged, characterized by the equivalent
circulation of NDM and KPC. K. pneumoniae remains the primary species responsible
for their dissemination. The co-production of carbapenemase combinations,
particularly KPC plus NDM, was confirmed, mainly in K. pneumoniae. High activity
was observed for AZA against MBLs and for CZA and IMR against KPC and OXA-163
carbapenemases.
Descripción : 
Fil: Echegorry M. Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán"; Buenos Aires, Argentina.

Fil: Marchetti P. Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán"; Buenos Aires, Argentina.

Fil: Sanchez C. Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán"; Buenos Aires, Argentina.

Fil: Olivieri L. Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán"; Buenos Aires, Argentina.

Fil: Faccone D. Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán"; Buenos Aires, Argentina.

Fil: Martino F. Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán"; Buenos Aires, Argentina.

Fil: Sarkis Badola T. Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán"; Buenos Aires, Argentina.

Fil: Ceriana P. Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán"; Buenos Aires, Argentina.

Fil: Rapoport M. Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán"; Buenos Aires, Argentina.

Fil: Lucero C. Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán"; Buenos Aires, Argentina.

Fil: Albornoz E. Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán"; Buenos Aires, Argentina.

Fil: Recapt-Ar Group. Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán"; Buenos Aires, Argentina.

Fil: Corso A. Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán"; Buenos Aires, Argentina.

Fil: Pasteran F. Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán"; Buenos Aires, Argentina.
URI : http://sgc.anlis.gob.ar/handle/123456789/2634
DOI: https://doi.org/10.3390/antibiotics13121139
Aparece en las colecciones: Publicaciones INEI

Ficheros en este ítem:
Fichero Descripción Tamaño Formato
antibiotics-13-01139.pdfEnglish; 19 pages641.76 kBAdobe PDFVisualizar/Abrir
Mostrar el registro Dublin Core completo del ítem

Visualizaciones de página(s)

59
comprobado en 14-jun-2025

Descarga(s)

7
comprobado en 14-jun-2025

Google ScholarTM

Consultar

Altmetric

Altmetric


Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.